MAIA Biotechnology Files 8-K: Material Agreement & Equity Sales
Ticker: MAIA · Form: 8-K · Filed: May 6, 2025 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
MAIA Bio inked a big deal and sold some stock, filing an 8-K on 5/5/25.
AI Summary
On May 5, 2025, MAIA Biotechnology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This filing indicates significant corporate activity for MAIA Biotechnology, Inc., including a material definitive agreement and potential equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity securities, which can introduce financial and operational risks.
Key Numbers
- 001-41455 — Commission File Number (Identifies the company's SEC filing history.)
- 83-1495913 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- May 5, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41455 (company_id) — Commission File Number
- 444 West Lake Street, Suite 1700 (address) — Principal executive offices
- Chicago, IL 60606 (address) — Principal executive offices
- 312-416-8592 (phone_number) — Registrant's telephone number
FAQ
What type of material definitive agreement did MAIA Biotechnology, Inc. enter into?
The filing states that MAIA Biotechnology, Inc. entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is May 5, 2025.
Where are MAIA Biotechnology, Inc.'s principal executive offices located?
MAIA Biotechnology, Inc.'s principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What is the Commission File Number for MAIA Biotechnology, Inc.?
The Commission File Number for MAIA Biotechnology, Inc. is 001-41455.
What are the main items reported in this 8-K filing?
The main items reported are Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, and Financial Statements and Exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding MAIA Biotechnology, Inc. (MAIA).